Connect with us

Technology

Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024

Published

on

225Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical developmentSatoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a higher pre-clinical anti-tumour efficacy, irrespective of radionuclide used100% survival with a single dose of 30 kBq 225Ac-satoreotide but not with 225Ac-DOTA-TATE

BERLIN, Oct. 22, 2024 /PRNewswire/ — Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it presented data on its proprietary radiolabelled peptide SS0110 (satoreotide), a first-in-class antagonist of the somatostatin receptor 2 (SSTR2), at this year’s European Association of Nuclear Medicine (EANM) Annual Conference, held in Hamburg, Germany from 19-23 October 2024.

The Top-Rated Oral Presentation (TROP) entitled ‘225Ac-SSO110 induces long-lasting anti-tumour responses in contrast to 225Ac-DOTA-TATE and 161Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts’, details the anti-tumour efficacy of different radiolabelled satoreotide antagonists (225Ac, 161Tb, 177Lu-labelled SSO110) versus respective DOTA-TATE agonists (225Ac- and 161Tb-labelled DOTA-TATE) in mice engrafted with SSTR2 positive xenografts of small cell lung cancer (SCLC) and pancreatic cancer using clinically relevant associated dose ranges.  

Results demonstrate that 225Ac-satoreotide shows the strongest anti-tumoural effect in vivo at a low single dose when evaluating satoreotide and DOTA-TATE radiolabelled with different radionuclides. Irrespective of the radionuclides used, satoreotide demonstrated a higher pre-clinical anti-tumour efficacy when compared to DOTA-TATE which was less potent and required increased dose levels. Satoreotide was well tolerated across all dose levels and with all used radionuclides. These comparisons between satoreotide and DOTA-TATE will facilitate and guide further clinical development of satoreotide across multiple indications expressing SSTR2, such as SCLC, pancreatic cancers and Merkel Cell Carcinoma (MCC).

Previous comparisons between satoreotide and DOTA-TATE demonstrated that antagonist, 225Ac-satoreotide, is multiple times more potent than SSTR2 agonist, 225Ac-DOTA-TATE, signifying a durable complete response in standard murine xenograft models of SCLC in animal models, versus tumour growth delay.

Ariceum had previously shown at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 that 212Pb was not seen to be more potent than Lutetium or Terbium but caused more side effects and hence was not further pursued.

Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: “These results provide strong evidence for satoreotide and its potential to clinically outperform SSTR2 targeting agonists, by demonstrating significantly better efficacy in tumour growth control, up to complete tumour eradication depending on isotope used. In addition, when a single dose of 30 kBq 225Ac-satoreotide was administered, we observed high frequency of complete durable responses and 100% survival which strongly supports further clinical development for the treatment of SCLC, MCC and other cancers.”

Details of the oral presentation are as follow:

Title: 225Ac-SSO110 induces long-lasting anti-tumour responses in contrast to 225Ac-DOTA-TATE and 161Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts

Presenting Author: Prachi Desai, Scientist at Ariceum Therapeutics

Session Number: 1204
Session Title: M2M Track – TROP Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: From Radionuclide to Clinical Translation

Oral Presentation Date & Time: Tuesday 22 October 2024, 09:00 AM09:10 AM CEST

Abstract Authors: Prachi Desai, Manuel Sturzbecher
–  Hoehne,
Dennis Mewis, Manfred Ruediger & Anika Jaekel  of Ariceum Therapeutics

Abstracts are available in the September edition of Springer’s European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) abstract book here and on the Ariceum website here.

About Ariceum Therapeutics

Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer.

Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“Satoreotide”), is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), or Merkel Cell Carcinoma (MCC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023.

Ariceum Therapeutics, launched in 2021, acquired all rights to Satoreotide from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, United Kingdom and United States of America and with activities currently across the globe.

Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners and Earlybird Venture Capital. For further information, please visit www.ariceum-therapeutics.com.

About European Association of Nuclear Medicine (EANM)

The European Association of Nuclear Medicine (EANM) is a non-profit organization that promotes nuclear medicine and aims to improve public health. The EANM’s mission is to advance nuclear medicine through personalized healthcare, innovation in diagnosis and treatment, and raising awareness of nuclear medicine

View original content:https://www.prnewswire.co.uk/news-releases/ariceum-therapeutics-presents-outstanding-data-on-its-first-in-class-radiopharmaceutical-drug-225ac-satoreotide-at-the-european-association-of-nuclear-medicine-2024-302282011.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

ZTO to Announce Third Quarter Financial Results of 2024 on November 19, 2024 U.S. Eastern Time

Published

on

By

SHANGHAI, Oct. 22, 2024 /PRNewswire/ — ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) (“ZTO” or the “Company”), a leading and fast-growing express delivery company in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 after the U.S. market closes on November 19, 2024.

ZTO’s management team will host an earnings conference call at 7:30 P.M. U.S. Eastern Time on Tuesday, November 19, 2024, which is 8:30 A.M. Beijing Time on Wednesday, November 20, 2024.

Dial-in details for the earnings conference call are as follows:

United States:

1-888-317-6003

Hong Kong:

800-963-976

Singapore:   

800-120-5863

Mainland China:

4001-206-115

International:

1-412-317-6061

Passcode:

0501133

A replay of the conference call may be accessible through November 26, 2024 by dialing the following numbers: 

United States:   

1-877-344-7529

International:

1-412-317-0088

Canada:

855-669-9658

Passcode:

1609584

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at http://zto.investorroom.com.

About ZTO Express (Cayman) Inc.

ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) (“ZTO” or the “Company”) is a leading and fast-growing express delivery company in China. ZTO provides express delivery service as well as other value-added logistics services through its extensive and reliable nationwide network coverage in China.

ZTO operates a highly scalable network partner model, which the Company believes is best suited to support the significant growth of e-commerce in China. The Company leverages its network partners to provide pickup and last-mile delivery services, while controlling the mission-critical line-haul transportation and sorting network within the express delivery service value chain.

For more information, please visit http://zto.investorroom.com.

For investor inquiries, please contact:

Investor Relations
Tel: (86) 21 5980 4508
Email: ir@zto.com

View original content:https://www.prnewswire.com/news-releases/zto-to-announce-third-quarter-financial-results-of-2024-on-november-19-2024-us-eastern-time-302282625.html

SOURCE ZTO Express (Cayman) Inc.

Continue Reading

Technology

Hisense’s Overseas Annual Revenue Surpasses $12.2 Billion USD

Published

on

By

Hisense Group Announces New Goals for the Future at 55th Anniversary

QINGDAO, China, Oct. 22, 2024 /CNW/ — Hisense, a leading brand in global consumer electronics and home appliances, announced a remarkable milestone with its overseas business revenue surpassing $12.2 billion USD in the fiscal year of 2023. This significant achievement was revealed at the Group’s 55th-anniversary celebrations, at which the company also unveiled its ambitious future goals.

Over the past five years, Hisense has significantly expanded its global footprint and achieved breakthroughs in technological foundation. The company’s acquisition of SanDen Corporation and development of AI picture quality chips were catalysts for growth, enabling Hisense to enter new markets and enhance its technological capabilities. As a result, Hisense’s overseas revenue has more than doubled since 2019, while in 2023 Hisense Group’s revenue surpassed $28.7 billion USD.

At the celebration event, Hisense Group Chairman, Mr. Jia Shaoqian, delivered the speech “Faithful as in the Beginning, Creating the Future”, introducing future goals, including becoming a high-quality development model by leveraging industrial clusters; transitioning towards green and low-carbon operations; expanding its global reach through transformation from China-centric to a truly global management model; and establishing a world-class enterprise and global brand.

“We continue to strengthen our core competitiveness in technology and products, leverage strong appeal in cross-cultural integration, and enhance global competitiveness in building a brand matrix,” emphasized Mr. Jia. “Hisense will persist in developing our own brands, aiming for the high-end market in resolutely striving to become world-class!”

With a focus on innovation, Hisense has dedicated approximately 5% of its annual revenue to R&D, with 30% of that investment directed towards pre-research. By prioritizing user needs and customer satisfaction, Hisense ensures that its products and technologies serve users and create value.

Hisense has established a strong global presence with 36 industrial parks and production bases, 30 R&D centers, and 64 overseas offices, forming a “5+1” network covering Europe, the Americas, ASEAN, the Middle East, Africa, and China. To drive growth, Hisense is accelerating its manufacturing footprint globally. In Africa, the company is establishing new production facilities, while in ASEAN and Latin America, Hisense is increasing localizing production and research capabilities. This strategic expansion will enable Hisense to better serve customers and strengthen its global competitive position.

With the vision of building a “Century-old Company”, Hisense is committed to ongoing improvements in corporate governance. By benchmarking against global best practices, fostering board diversity, and implementing a more robust structure, the company aims to enhance its governance level and accelerate its journey towards becoming a world-class enterprise.

About Hisense

Hisense is a leading global home appliance and consumer electronics brand and official partner of the UEFA EURO 2024™. According to Omdia, Hisense ranked No. 2 globally for TV shipments and No. 1 in 100″ TVs in both 2023 and H1 2024. The company has expanded quickly to operate in more than 160 countries and specializes in multi-media goods, home appliances, and intelligent IT information.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hisenses-overseas-annual-revenue-surpasses-12-2-billion-usd-302282894.html

SOURCE Hisense

Continue Reading

Technology

HSG Laser Boosts European Presence with Advanced Technologies and Comprehensive Service Network at EuroBLECH 2024

Published

on

By

HANOVER, Germany, Oct. 22, 2024 /PRNewswire/ — At EuroBLECH, HSG Laser, a global leader in metal shaping equipment and automation solutions, unveils its ambitious European growth strategy. This plan encompasses the launch of cutting-edge industry solutions and commitment to active engagement through local events. Aligned with the fair’s theme, “The Power of Productivity”, HSG showcases three advanced cutting technologies designed to elevate productivity and drive growth for its global customers.

Over the past six years, HSG has cultivated a strong presence in the German market, earning customer trust through dedicated local services. The Düsseldorf headquarters, a vital hub for sales, after-sales support, and logistics, features a showroom and well-stocked warehouse with a broad range of products and spare parts for fast delivery.

With an installation base of over 25,000 machines across more than 100 countries, HSG has gained a strong reputation in the global market by offering high-quality equipment at competitive prices.

GV: A Cutting-Edge 2D Laser Cutting Solution

After making its debut in the U.S. market, the GV model gains significant attention at the German fair. Equipped with a powerful 60kW fiber laser, this system can cut materials up to 10cm thick at speeds up to 400% faster than conventional 12kW machines. The GV integrates seamlessly into existing product lines and features an optional automation Tower for material handling, presenting an ideal choice for manufacturers aiming to maximize productivity at low cost.

X: Optimized Laser Cutting Machine for Space Efficiency

HSG also displays the X model, engineered to maximize processing efficiency within a minimal footprint. With a maximum linkage speed of 120m/min and acceleration of 1.5G, the machine delivers outstanding performance in a compact format, ideal for facilities with limited floor space. Safety remains a top priority, as the X model features a fully enclosed structure, optical density glass to shield against laser radiation, and enhanced safety measures to protect operators.

TX: Ultimate Solution for Heavy-Duty Tube Cutting

For industries including steel construction and bridge building, HSG’s TX offers unmatched capabilities. It processes heavy-duty tubes such as round tubes up to 36cm in diameter and 12m in length with precision, supported by HSG’s self-developed 3+1 Twin Chucks clamping system that minimizes waste and enhances cutting accuracy.

By presenting its state-of-the-art cutting technologies, HSG reaffirms its commitment to the European market, and to support its clients in achieving their manufacturing objectives.

View original content:https://www.prnewswire.co.uk/news-releases/hsg-laser-boosts-european-presence-with-advanced-technologies-and-comprehensive-service-network-at-euroblech-2024-302282455.html

Continue Reading

Trending